Information  X 
Enter a valid email address

Zoetic Interntnl PLC (ZOE)

  Print   

Thursday 31 December, 2020

Zoetic Interntnl PLC

Update on Sale of DTU

RNS Number : 1950K
Zoetic International PLC
31 December 2020
 

Prior to publication, the information contained within this announcement was deemed by the Company to constitute inside information for the purposes of Article 7 under the Market Abuse Regulation (EU) No. 596/2014 ("MAR"). With the publication of this announcement, this information is now considered to be in the public domain.

 

31 December 2020

 

Zoetic International plc

 

("Zoetic" or the "Company" or the "Group")

 

Update on Sale of DTU

 

Further to the announcement of 5 November 2020, Zoetic International plc (LSE: ZOE), the London-listed vertically integrated CBD company, confirms that the revised long-stop date for completion of the revised agreement to sell its 75 per cent interest in DT Ultravert ("DTU") to Path Investments plc ("Path"), has not been achieved (the "Transaction"). 

 

The Company remains committed to its policy of exiting its legacy natural resources activities and the Directors will actively investigate solutions in relation to its interest in DTU, including continuing discussions with Path, as well as its Kansas Nitrogen and other natural resources assets.

 

Trevor Taylor, Co-CEO of Zoetic, commented, "We are committed to achieve the best deal possible for our shareholders, and will look at all possible options."

 

 

**ENDS**

Enquiries

 

Zoetic International plc   c/o IFC Advisory

Trevor Taylor, Co-CEO

 

Allenby Capital Limited (Financial Adviser and Broker)                                              +44 (0) 20 3328 5656

Nick Harriss (Corporate Finance)

Nick Naylor (Corporate Finance)

Guy McDougall (Equity Sales)

 

IFC Advisory Ltd (Financial PR and IR)                                                                             +44 (0) 20 3934 6630

Tim Metcalfe

Graham Herring

Florence Chandler

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDFDWFMSESSEDE

a d v e r t i s e m e n t